Synthetic biology startup D-Nome receives $1.5 million from Campus Fund and Ankulr Capital
- ByStartupStory | January 21, 2023
D-Nome, a business in synthetic biology, received $1.5 million in seed money from Ankur Capital, Campus Fund, and additional investors.
D-deviceless Nome’s PCR technology aims to democratise molecular diagnostics.
The Centre of Cellular and Molecular Biology’s PhD students Divya Sriram and Sujoy Deb founded the firm in July 2021 with the goal of developing quick point-of-care diagnostics for human infectious diseases and other applications using genomics and synthetic biology.
“Our mission is to fill the gap in testing and enable personalised medicine at scale, something that has not been successful due to the lack of scalable and accurate diagnostic tools. We hope to create significant impact socially and economically for developing nations and pave the way for next-generation healthcare relying heavily on genomics,”
Currently, there are three main testing methods: ordinary culture, which takes time and infrastructure to perform, rapid antigen/antibody tests, which are quicker but less accurate, and PCR/ Real time PCR (RT-PCR) tests, which are the most accurate but costly and labor-intensive.
Follow Startup Story
Related Posts
